company background image
5246

Welcure Drugs & Pharmaceuticals BSE:524661 Stock Report

Last Price

₹5.93

Market Cap

₹76.3m

7D

4.0%

1Y

145.0%

Updated

17 May, 2022

Data

Company Financials
524661 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

524661 Stock Overview

Welcure Drugs & Pharmaceuticals Limited engages in the wholesale of pharmaceutical and medical products in India.

Welcure Drugs & Pharmaceuticals Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Welcure Drugs & Pharmaceuticals
Historical stock prices
Current Share Price₹5.93
52 Week High₹12.08
52 Week Low₹2.42
Beta0.22
1 Month Change-48.66%
3 Month Change-17.98%
1 Year Change145.04%
3 Year Change1,311.91%
5 Year Change123.77%
Change since IPO-40.70%

Recent News & Updates

Shareholder Returns

524661IN PharmaceuticalsIN Market
7D4.0%-1.6%-3.2%
1Y145.0%-11.0%9.0%

Return vs Industry: 524661 exceeded the Indian Pharmaceuticals industry which returned -11% over the past year.

Return vs Market: 524661 exceeded the Indian Market which returned 9% over the past year.

Price Volatility

Is 524661's price volatile compared to industry and market?
524661 volatility
524661 Average Weekly Movement9.8%
Pharmaceuticals Industry Average Movement6.9%
Market Average Movement7.2%
10% most volatile stocks in IN Market10.0%
10% least volatile stocks in IN Market4.7%

Stable Share Price: 524661 is more volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 524661's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company

FoundedEmployeesCEOWebsite
1996n/aSudhir Chandra

Welcure Drugs & Pharmaceuticals Limited engages in the wholesale of pharmaceutical and medical products in India. The company was incorporated in 1996 and is based in Delhi, India.

Welcure Drugs & Pharmaceuticals Fundamentals Summary

How do Welcure Drugs & Pharmaceuticals's earnings and revenue compare to its market cap?
524661 fundamental statistics
Market Cap₹76.34m
Earnings (TTM)₹236.00k
Revenue (TTM)₹1.05m

339.6x

P/E Ratio

76.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
524661 income statement (TTM)
Revenue₹1.05m
Cost of Revenue₹0
Gross Profit₹1.05m
Other Expenses₹814.00k
Earnings₹236.00k

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.017
Gross Margin100.00%
Net Profit Margin22.48%
Debt/Equity Ratio0.0%

How did 524661 perform over the long term?

See historical performance and comparison

Valuation

Is Welcure Drugs & Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


339.63x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: 524661 (₹5.93) is trading above our estimate of fair value (₹0.02)

Significantly Below Fair Value: 524661 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 524661 is poor value based on its PE Ratio (339.6x) compared to the Indian Pharmaceuticals industry average (21.1x).

PE vs Market: 524661 is poor value based on its PE Ratio (339.6x) compared to the Indian market (20.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 524661's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 524661 is overvalued based on its PB Ratio (86.2x) compared to the IN Pharmaceuticals industry average (2.5x).


Future Growth

How is Welcure Drugs & Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


19.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Welcure Drugs & Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Welcure Drugs & Pharmaceuticals performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


12.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 524661 has a high level of non-cash earnings.

Growing Profit Margin: 524661's current net profit margins (22.5%) are lower than last year (41.3%).


Past Earnings Growth Analysis

Earnings Trend: 524661's earnings have grown by 12.7% per year over the past 5 years.

Accelerating Growth: 524661's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 524661 had negative earnings growth (-57.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.4%).


Return on Equity

High ROE: 524661's Return on Equity (25.4%) is considered high.


Financial Health

How is Welcure Drugs & Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 524661's short term assets (₹660.0K) exceed its short term liabilities (₹38.0K).

Long Term Liabilities: 524661 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 524661 is debt free.

Reducing Debt: 524661 has not had any debt for past 5 years.

Debt Coverage: 524661 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 524661 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Welcure Drugs & Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 524661's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 524661's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 524661's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 524661's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 524661 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.5yrs

Average management tenure


CEO

Sudhir Chandra (84 yo)

10.25yrs

Tenure

₹84,000

Compensation

Mr. Sudhir Chandra, B.Sc., B. Tech (Hons.), Dip. (Ing) has been the Managing Director and Director at Welcure Drugs & Pharmaceuticals Ltd. since February 1, 2012 and December 31, 2005 respectively.Mr. Cha...


CEO Compensation Analysis

Compensation vs Market: Sudhir's total compensation ($USD1.08K) is below average for companies of similar size in the Indian market ($USD38.73K).

Compensation vs Earnings: Sudhir's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 524661's management team is seasoned and experienced (6.5 years average tenure).


Board Members

Experienced Board: 524661's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Welcure Drugs & Pharmaceuticals Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Welcure Drugs & Pharmaceuticals Limited
  • Ticker: 524661
  • Exchange: BSE
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹76.343m
  • Shares outstanding: 13.51m

Location

  • Welcure Drugs & Pharmaceuticals Limited
  • B-9 and 10, Laxmi Towers
  • L.S.C., Block C
  • Delhi
  • Delhi
  • 110034
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/17 00:00
End of Day Share Price2022/05/17 00:00
Earnings2022/03/31
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.